The Mdm2 gene is overexpressed in several human tumors. The oncogenic potential of Mdm2 is partially explained by the inhibition of the activity of the tumor suppressor protein p53. Determination of the threedimensional structure of complexes between Mdm2 and the N-terminal p53 peptide provided a molecular basis for the inhibition of the transcriptional function of p53 by Mdm2. More dramatically, p53 is targeted by Mdm2 for rapid degradation. The Mdm2 gene itself is activated by p53, which gives the opportunity for feed-back control of p53 activity. Keeping p53 under control is most likely the major task of Mdm2 during early development. Recently, evidence was provided for an alternative, p53-independent function of Mdm2.
Introduction
The Mdm2 gene appeared as a new type of protooncogene through the ability of its product to neutralize the activity of tumor suppressors, reminiscent of oncoproteins of DNA tumor viruses such as SV40 large T antigen. The main tumor suppressor protein targetted by Mdm2, p53, is known to be mutated in more than 50% of human tumors (Hollstein et al., 1991) and is a key element in the protection against tumor development. The role of p53 in the DNA damage checkpoint is now clearly established (Kastan et al., 1991) , and recent results also implicate the protein in the spindle formation checkpoint and in the response to depletion of oxygen or ribonucleotides (Minn et al., 1996; Graeber et al., 1996; Linke et al., 1996) . Activation of p53 by DNA damage or other stresses leads to cell cycle arrest or to apoptosis. These cellular responses are mediated, at least in part, by the ability to stimulate gene expression. In this way, functional p53 prevents the proliferation of potential tumorigenic cells. Numerous reviews and comments have been published concerning p53, yet, until now, Mdm2 was only brie¯y discussed (with the exception of Picksley and Lane, 1993; Perry and Levine, 1994 and more recently Momand and Zambetti, 1997) . Recent exciting developments concerning Mdm2 fully justify dedication of a complete review to this intriguing protein, which does more than control p53. Nevertheless, because these two proteins are so intricately involved, a brief overview of the biology of p53 would be desirable before focusing on Mdm2 (for recent reviews see Bates and Vousden, 1996; Kastan, 1996; Soussi and May, 1996; Levine, 1997; Hansen and Oren, 1997) .
From double minute chromosomes to p53
Mdm2 (murine double minute gene 2) was ®rst described as one of the genes ampli®ed on the double minute chromosomes present in the spontaneously transformed Balb/c3T3 murine cell line 3T3DM (Cahilly-Snyder et al., 1987) . The ampli®ed sequences originate from chromosome 10, region C1-C3. NIH3T3 or Rat2 cells overexpressing only the cloned Mdm2 gene were tumorigenic in nude mice, indicating that Mdm2 by itself possesses transforming activity (Fakharzadeh et al., 1991) . Independently, characterization of a 90 kD protein associated with p53 (Hinds et al., 1990; Barak and Oren, 1992) led to the identi®cation of this protein as a product of the Mdm2 gene (Momand et al., 1992) . Of crucial importance for the understanding of the biological role of Mdm2 was the observation that its overexpression led to inhibition of p53-mediated transactivation (Momand et al., 1992) , probably by concealing the activation domain of p53 (Oliner et al., 1993; Chen et al., 1993) . Cloning of the human homolog of Mdm2 allowed con®rmation of the interaction between p53 and Mdm2, and implication of Mdm2 in human oncogenesis. Indeed, the locus containing the Mdm2 gene, 12q13-14, was found ampli®ed in over a third of 47 human sarcomas (Oliner et al., 1992) . This observation led to the hypothesis that overexpression of Mdm2 could provide an alternative to mutation as a mean of inactivating p53 during the process of tumorigenesis.
Structure and function of Mdm2 protein: the p53 binding domain
The full length mouse Mdm2 protein is composed of 489 amino acids (aa) (Fakharzadeh et al., 1991) . A comparison between the primary sequences of murine, human (491 aa) (Oliner et al., 1992) , Xenopus laevis (473 aa) (Marechal et al., 1997) and zebra®sh Mdm2 (445 aa) (HN and JP, unpublished) allows identification of four major conserved regions (Figures 1 and 2 ). Region I includes about 90 aa of the N-terminus lacking obvious sequence domains (46% identity), region II is included in a highly acidic region (62% identity), region III contains a potential zinc ®nger (58% identity), region IV contains a ring-®nger (83% identity) (Boddy et al., 1994) . A short basic region with a potential nuclear localization signal is also conserved (Fakharzadeh et al., 1991) .
Much eort has been devoted to the characterization of the region of Mdm2 that binds to p53. This domain was mapped by co-immunoprecipitation experiments and functional assays between aa 14 ± 130 for the mouse protein (Leng et al., 1995) and between aa 19 ± 102 for the human protein Oliner et al., 1993) , which closely corresponds to region I. Sequences outside this core domain may help to stabilize the interaction between the two proteins . The Mdm2 binding domain on p53 was narrowed down to the 15-residue peptide subsequently used in co-crystalization experiments.
Using synthetic peptides Picksley and colleagues identi®ed the residues TFSDLW (aa 18 ± 23) as essential for binding to human Mdm2 (Picksley et al., 1994) while Lin and colleagues identi®ed residues, L14, F19, L22 and W23 by a mutational approach. Residues L22 and W23 are also required for transcriptional activation by p53 or binding to TAF II 31, demonstrating an overlap between the transactivation domain and the Mdm2 binding domain of p53 (Lin et al., 1994; Lu and Levine, 1995) . The three-dimensional structure of a 109-residue amino-terminal domain of Xenopus laevis Mdm2 bound to the 15-residue transactivation domain peptide of p53 revealed that Mdm2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic a helix (Kussie et al., 1996;  Figure 3 ). Residues F19, W23 and L26 of p53 insert deeply into Figure 2 . The nuclear localization signal (nls) sequence is hypothetic (Fakharzadeh et al. 1991) . See text for further details Figure 2 A comparison between Mdm2 homologs from dierent vertebrate species. Identical residues are labeled by a star, similar residues by a point below the sequences. Residues of region I in close contact with the p53 helix are shadowed (Kussie et al. 1996) as are cysteines, histidines and threonines potentially involved in the structure of the zinc-®nger in region II and the ring-®nger in region IV. The putative nls is boxed. Known Mdmx homologs are shown also with residues shared with the Mdm2 homologs indicated below the sequence. The homologs are from the following species: Danio rerio (HN Soussi and May, 1996) . Mdmx, a new member of the Mdm2 family was recently isolated and binds to p53, potentially in a manner similar to that by which Mdm2 binds (Shvarts et al., 1996) . A p53-Mdm2 complex may even exist in invertebrates because the p53 homolog of squids contains an almost perfect conservation of the Mdm2 binding residues (P Winge and S Friend, unpublished observations cited in Soussi and May, 1996) .
Which functions of p53 are controlled by Mdm2? At least all those that require the interaction of p53 with the transcription machinery. Indeed, in addition to inhibiting transactivation of p53 responsive genes, Mdm2 was shown to inhibit the repression of TATAbox containing promoters by p53 or the activation of the multidrug resistance-1 promoter by mutant p53 . Thus, it is likely that the ability of Mdm2 to reverse the arrest of cell division mediated by p53 is due to the ability of Mdm2 to counteract the induction by p53 of cell cycle inhibitory genes such as Cip1 (Chen et al., , 1996 . The in¯uence of Mdm2 expression on p53 dependent apoptosis is less clearcut, perhaps because other activities of p53, in addition to its transcriptional regulatory functions, can contribute to p53-mediated apoptosis (reviewed in Bates and Vousden, 1996) . However, in several cases it is clear that Mdm2 is a negative regulator of apoptosis. Overexpression of Mdm2 decreased the susceptibility of human glioblastoma cells to apoptosis induced by cisplatin, while expression of antisense Mdm2 increased their susceptibility (Kondo et al., 1995) . p53 dependent apoptosis induced by c-myc overexpression was inhibited by Mdm2, and this inhibition did not require the acidic domain or the zinc-®ngers of the protein (Chen et al., 1996) . Also, protection from apoptosis in human H1299 cells was dependent on the formation of a p53-Mdm2 complex . Thus, existing evidence is in favor of a protective role of Mdm2 against apoptosis by virtue of its targeting p53.
It was shown recently that complex formation between Mdm2 and p53 leads to rapid degradation of p53 by the proteasome (Haupt et al., 1997; Kubbutat et al., 1997) . It is then also likely that all known activities of p53 will be reduced by Mdm2, with transcriptional activities more severely aected 
Additional functions for the N-terminal domain: promoting S-phase entry?
The N-terminal domain of Mdm2 was also shown to stimulate the transactivation of reporter genes by E2F-1/DP1, a transcription factor that plays an essential role in the G1-S phase transition (Martin et al., 1995) . Interestingly, Mdm2 contacts amino acid residues in the activation domain of E2F-1 similar to those present in the Mdm2-binding domain of p53, suggesting that Mdm2 may interact with other proteins using similar protein-protein interaction motifs. Mdm2 was also found to interact with pRb, a tumor suppressor protein known to inhibit E2F-1-dependent transcription (Xiao et al., 1995) . Whatever the way Mdm2 activates E2F-1 responsive genes, be it by interfering with pRb function and/or by direct stimulation of E2F-1 activity, this newly discovered function may, together with the inactivation of p53, contribute to the recovery of cellular proliferation after repair of DNA damage.
The central acidic domain: a link with translation?
Region II is composed of 37% acidic residues in mouse and human. Highly acidic regions are often characteristic for transactivation domains, and regions encompassing the acidic region of Mdm2 do have transcriptional activity in yeast cells when fused to the Lex-A DNA binding domain (Oliner et al., 1993) . However, the same domain linked to the GAL4 DNAbinding domain has no transcriptional activity in transient expression assays in mammalian cells (HN and JP, unpublished observations) . A possible function in ribosome biosynthesis or in translational regulation is suggested by the speci®c interaction of this Mdm2 domain with L5 protein, a component of the large ribosomal subunit, which is itself associated with 5S rRNA (Marechal et al., 1994; Elenbaas et al., 1996) . The Mdm2-L5 interaction was also found in Xenopus (Marechal et al., 1997) . In cells overexpressing Mdm2, there are tertiary complexes containing Mdm2, L5 and 5S rRNA as well as quaternary complexes of Mdm2, p53, L5 and 5S rRNA (Marechal et al., 1994) . Similarly to Mdm2 , 5S rRNA-L5 protein complexes are found in the nucleoplasm of mammalian cells where they serve as a precursor pool for ribosome biosynthesis (Steitz et al., 1988) . Mdm2 may thus regulate their availability for incorporation into the large ribosomal subunit. Alternatively, Mdm2 may regulate another function of the L5 protein which is the transport of 5S rRNA between cytoplasm and nucleus (Guddat et al., 1990; Rudt and Pieler, 1996; Murdoch and Allison, 1996) . Altogether, regulation of ribosome metabolism may be an important novel function of Mdm2. Figure 4 A comparison between the ring-®ngers of the Mdm2, Neuralized and IAP classes of proteins. Identical residues are shadowed in dark grey whereas similar residues are in light grey. CNEU is the neuralized homolog of Caenorhabditis elegans (Wilson and al., 1994) ; DNEU is neuralized from Drosophila melanogaster (Boulianne et al., 1991) ; IAP homologs are from the following species: IAPC, Cydia pomonella granulosis virus (Crook et al., 1993) ; IAPO, Orgyia pseudotsugata nuclear polyhedrosis virus (Birnbaum et al., 1994) ; IAPA, Autographa californica nuclear polyhedrosis virus (Ayres et al., 1994) ; DIAP, Drosophila melanogaster (Liston et al., 1996) ; XIAP, HIAP1 and HIAP2, Homo sapiens (Liston et al., 1996) and MIAP2, Mus musculus (Rothe et al., 1995) Fingers: what for?
Still obscure is the function of the central C-X 2 -C-X 10 -C-X 2 -C zinc-®nger like sequence enclosed in region III. More information is available on the C-terminal ring®nger like domain which shows a remarkable conservation between species (region IV). It is a nonclassical ring-®nger of structure C-X 2 -C-X 13 -T-X-H-X 3 -C-X 2 -C-X 10 -C-X 2 -C with a stretch of basic residues between the C-terminal cysteine pairs (Boddy et al., 1994) . Selection of RNA sequences binding to Mdm2 with high anity yielded a series of highly related RNAs. The ring-®nger was found to be responsible for this interaction and, interestingly, a single amino acid substitution was sucient for disrupting the interaction of Mdm2 with RNA . The ring®ngers showing the greatest homology with those of Mdm2 in regard to both the primary sequence and the exact location with respect to the C-terminus are the ring-®ngers of two classes of proteins represented by neuralized and IAP (Boulianne et al., 1991; Crook et al., 1993; Figure 4) . Neuralized was shown to be involved in neurogenesis in Drosophila, while IAP proteins are a large family of proteins with antiapoptotic activity which are represented in both vertebrates and invertebrates (Liston et al., 1996) . The exact function of the ring-®nger in these proteins is not known.
Mdm2 gene structure and expression
What can the structure of the Mdm2 gene teach us about its regulation? The mouse gene contains at least 12 exons spread over about 25 kb of DNA (Montes de Oca Luna et al., 1996; Jones et al., 1996) . Two promoters were characterized: the ®rst one is located upstream of the gene and is expressed constitutively whereas the second one is present in the ®rst intron and is controlled by p53 in both mouse and human through two adjacent p53 binding sites (Wu et al., 1993; Juven et al., 1993; Barak et al., 1994; Zauberman et al., 1995) . Activation of Mdm2 expression by p53 provides the opportunity for feedback control of p53 activity that could play an important role in cell recovery after repair of damaged DNA. Interestingly, the two promoters give rise to transcripts with alternative coding potential in vitro; translational initiation at internal start-codons leads to truncated proteins unable to bind p53. Such forms are translated preferentially from the longer transcript under certain conditions (Barak et al., 1994) . Possibly related to this observation, proteins of lower apparent molecular weight missing the N-or C-terminal region are often present in addition to p90, albeit in smaller amounts M Oren, personal communication) . However, experimental manipulation of the ratio between the transcripts originating from the two promoters did not modify the ratio between full length and truncated protein forms in LTR6 cells (Barak et al., 1994) . Also, the full length p90 form of Mdm2 was detected predominantly in human keratinocytes, even in the absence of functional p53 (Dazard et al., 1997) . Several alternatively spliced transcripts were detected in transformed cell lines or tumors, some of them giving rise also to proteins having lost the ability to bind p53 Maxwell, 1994; Sigalas et al., 1996) . However, no evidence was found for their existence in normal physiological situations (Montes de Oca Luna et al., 1996) . Thus, N-terminally truncated forms may be produced by internal translational initiations or alternative splicing events, but may occur less frequently in normal physiological situations than in tumors or transformed cell lines.
Mdm2: oncogene sensu stricto or anti-tumor suppressor?
Directly related to the existence of alternative functions for Mdm2 is the question of how it transforms cells. It is mainly by inactivating the transcriptional regulatory function of p53 or can it occur by other mechanisms also? A careful analysis of the panel of tumors in which alterations of p53 and/or Mdm2 were observed can give us interesting indications concerning the equivalence of these events. Mdm2 was found to be ampli®ed in about 20% of soft tissue sarcomas. Other tumors with frequent ampli®cations of the Mdm2 gene are astrocytomas, esophageal tumors, osteosarcomas or testicular germ cell tumors (reviewed in Momand and Zambetti, 1997) . A ®rst restriction to this approach is that in many cases only gene ampli®cation was measured, while rarely were mRNA or protein levels investigated. This may lead to an underestimation of the real impact of the contribution of deregulated expression of Mdm2 to tumorigenesis. Indeed, if in most cases analysed gene ampli®cation was accompanied by overexpression of the protein (e.g. Leach et al., 1993; Marchetti et al., 1995) , overexpression of the protein without gene ampli®cation was also observed (e.g. McCann et al., 1995; Landers et al., 1994) . This was due to gene translocation in the mouse plasmacytoma cell line SP2 or enhanced translation in human choriocarcinoma cell lines (Berberich and Cole, 1994; Landers et al., 1994) . Absence of ampli®cation of Mdm2 seems to be the rule in blood cancers (BuesoRamos et al., 1993; Schottelius et al., 1994; Quesnel et al., 1994; Zhou et al., 1995) . Secondly, ampli®cation of the 12q13-14 region often includes the CDK4 gene and adjacent genes which could also be involved in the process of tumorigenesis (Khatib et al., 1993) . Only in a few cases was the absence of a co-ampli®cation of Mdm2 and CDK4 demonstrated (Ladanyi et al., 1995; Nilbert et al., 1995) .
Simultaneous mutation of p53 and overexpression of Mdm2 was rarely observed. In an extensive study of 104 human carcinomas, 12 tumors or cell lines contained mutant p53, 10 overexpressed or ampli®ed Mdm2 and only one contained both p53 mutation and Mdm2 overexpression (Florenes et al., 1994) . This result is what one should expect if both events occur independently. In one study of soft tissue sarcomas, concomitant p53 mutation and Mdm2 overexpression was accompanied by a worse prognosis (Cordon-Cardo et al., 1994) while in another study of Sezary syndromes it coincided with the highest percentage of malignant cells (Marks et al., 1996) . The latter observations suggest that p53 mutation and Mdm2 overexpression are not completely redundant. Also, a high percentage of p53 mutations in one particular type of tumor does not necessarily mean a high percentage of Mdm2 overexpression (or vice versa).
Examples are chemically induced squamous cell carcinomas of the bucal pouch in hamster where seven of 22 tumors contained p53 mutations but none showed overexpression of Mdm2 mRNA (Chang et al., 1996) and pancreatic duct adenocarcinomas where ®ve of 19 tumors contained higher Mdm2 mRNA levels but none had p53 mutations (Chang et al., 1995) . This kind of tumor type speci®city also suggests that p53 mutation and Mdm2 overexpression are phenotypically not equivalent, although one cannot exclude that this speci®city is rather a re¯ection of the type of mutations occurring in dierent tumors (point mutations for p53 versus gene ampli®cations for Mdm2). More decisively, the recent discovery of mRNAs coding for N-terminally truncated forms of Mdm2 in bladder and ovary carcinomas, together with the ability of these mRNAs to transform cells, is a strong indication in favor of an oncogenic capacity of Mdm2 not related to the inactivation of p53 (Sigalas et al., 1996) .
Initial experimental evaluation of the transforming potential of the Mdm2 gene was performed on cells expressing wild-type p53 (Fakharzadeh et al., 1991) and later work suggested that the oncogenic properties of Mdm2 were related to the inhibition of the growth suppressive properties of p53 by Mdm2 (Finlay, 1993) . Nevertheless, transformation of p53 null cells by Mdm2 overexpression could be obtained, and surprisingly, the N-terminal p53 binding domain was required to this end (Dubs-Poterszman et al., 1995) . The authors proposed that the abrogation of the p107-mediated G1 arrest by Mdm2 could be the mechanism by which Mdm2 leads to transformation.
Compelling evidence for a p53 independent transforming activity of Mdm2 was recently provided. Targetted overexpression of an Mdm2 minigene in the mammary gland led to uncontrolled entry into Sphase, polyploidy and tumor formation both in p53 wild type and p53 null mice (Lundgren et al., 1997) . In conclusion, Mdm2 appears to be involved in cellular proliferation and transformation, not only through its ability to modulate p53's transcriptional activity, but also through additional functions which may be provided by both its N-terminal and C-terminal domains.
The p53-Mdm2 autoregulatory feedback-loop
The p53-Mdm2 autoregulatory feedback-loop model suggests that the activation of Mdm2 by p53 is required to reverse the inhibitory eects of p53 on cell cycle progression. Two crucial observations led to the proposal of this model: (i) the Mdm2 gene is one of the transcriptional targets of p53 protein (Wu et al., 1993; Barak et al., 1993) , and (ii) it is also a negative regulator of p53's transcriptional activity (Momand et al., 1992) . Thus, the activation of Mdm2 by p53 would automatically lead to the repression of the activity of the latter protein. Probably the most convincing argument in favor of this model is the observation that additional knock-out of the p53 alleles rescues Mdm2 null mice which normally die around the time of implantation (Montes de Oca Luna et al., 1995; Jones et al., 1995) . Also, in vitro experimental evidence was provided for a direct role of Mdm2 in the reversal of cell cycle arrest by p53 (Chen et al., , 1996 . These experiments clearly validate the model in its general outlines. However, its details are far from being understood. Indeed, its simple application would rapidly lead to a steady state situation without any opportunity for regulation and most importantly without a time lag for p53 to function. Most likely, additional regulations have to be superposed on this basic scheme to render it operational. We will consider brie¯y two additions to the basic p53-Mdm2 feedback loop model. In the ®rst one, transcriptional activation of Mdm2 by p53 is delayed, allowing p53 to do its job before it is repressed by its partner, in the second one it is the molecular interaction between both proteins that is retarted (see Figure 5a and b) . A variation of the ®rst model invokes a delay in the accumulation of Mdm2 protein by regulation of translation or protein stability. What is the experimental evidence, if any, in favor of these hypotheses?
Few studies have analysed in detail the induction of Mdm2 and the interaction between p53 and Mdm2 after a genotoxic insult. In an early study, the response of Mdm2 is activated together with cell cycle arrest and repair genes yet the molecular interaction between p53 and Mdm2 is possible only after repair of damaged DNA. (c) A basal expression of Mdm2 from the constitutive promoter p1 is responsible for maintaining low levels of p53. DNA damage leads to disruption of the p53-Mdm2 complex, stabilization of p53 and activation of the cellular response including activation of p2. After repair of DNA damage, accumulated Mdm2 rapidly degrades p53. See text for further details C127 cells to UV-C irradiation was investigated (Perry et al., 1993) . The induction of Mdm2 by u.v. light was p53-dependent; at low doses the induction of the gene was rapid while at higher doses a clear delay between p53 stabilization and Mdm2 induction was noticed. Transcriptional activation of target genes by p53 may thus be regulated under certain conditions. However, there is no evidence for dierential activation of p53 responsive genes in this study nor in u.v. irradiation experiments reported by Lu and coworkers (Lu et al., 1996) . Gamma-irradiation of human ®broblasts led to a rapid induction of Mdm2 mRNA. Unfortunately, no protein levels or G1 arrest were analysed in this study (Price and Park, 1994) . In another study, the Mdm2 gene was induced by gamma irradiation in a p53 dependent way, and overexpression of the gene resulted in reduced ability of the cells to arrest in G1 following irradiation . A detailed kinetic study revealed that the induction of Mdm2 was accompanied by increased ubiquitination of p53 followed by reduced p53 levels, suggesting that once synthesized, Mdm2 targets p53 for rapid degradation (Haupt et al., 1997) . Dierential activation by p53 of Mdm2 and growth inhibitory genes such as Cip1 remains an interesting issue which has to be further substantiated; although the promoters of both genes were mostly activated in a similar way Friedlander et al., 1996; Lohrum and Scheidtmann, 1996) , expression of Cip1 and Mdm2 could eectively be dissociated in two studies (Carrier et al., 1996; Knippschild et al., 1995) . This does not exclude, of course, that under certain circumstances Mdm2 is activated immediately by p53 and that in this case its main purpose is to attenuate the immediate eects of p53 induction (Bae et al., 1995; Guillouf et al., 1995) .
Another way to provide a time lag for DNA damage repair is a direct regulation of the complex formation between p53 and Mdm2 (Figure 5b ). In a study by Perry and colleagues a large proportion of both Mdm2 and p53 seemed to be uncomplexed, which suggested that the ability of both proteins to interact with each other could eectively be regulated (Perry et al., 1993) . Complex formation was studied in more detail by Momand and Zambetti who found that Mdm2 was bound to a variable subpopulation of p53 in dierent cell types: all p53 was bound in 3T3DM cells while no detectable Mdm2 was bound in Balb/c3T3 cells or normal ®broblasts (Momand and Zambetti, 1996) . Free Mdm2 was detected even when free p53 was present. However, no dierences in the phosphorylation levels of free or bound p53 were detected, suggesting that in the cases studied here, phosphorylation of p53 does not regulate its ability to interact with Mdm2. The presence of a DNA-PK phosphorylation site at serine 15 of human p53 provides an intriguing possibility for regulation of the interaction between the two proteins after DNA damage (Anderson and LeesMiller, 1992; Fiscella et al., 1993) . Replacement of this serine by alanine abolished binding of Mdm2 (Picksley et al., 1994) . In such a model, phosphorylation of p53 by DNA-PK or the related ATM kinase would interfere with Mdm2 binding. Only after repair of the lesions and inactivation of the kinase would complex formation and inactivation of p53's transcriptional activity occur. A variation of the latter model is schematized in Figure 5c . It postulates that a basal expression of Mdm2 could be maintained to keep a small population of p53 in the cell, which would be required to provide a quick response to DNA damage or other stresses. The p53 response may then be initiated by interfering with binding of Mdm2 to p53 as discussed before; this would lead to stabilization of p53 and activation of target genes. Absence of Mdm2 would then be equivalent to chronic activation of the p53 response. More work has clearly to be done to dierentiate between the dierent models.
The p53-Mdm2 feedback loop in development
The phenotypes of the Mdm2 and Mdm2 plus p53 null mice clearly indicate that Mdm2 is required to control p53 functions early during development. These early stages are more accessible in model organisms such as Xenopus laevis. The recent cloning of the cDNA of the Mdm2 homolog of Xenopus oers a tool to study the role of Mdm2 in this organism (Marechal et al., 1997) , in which essential structural and functional elements of the p53-Mdm2 feedback loop are known to be present (Cox et al., 1994; Wang et al., 1995; Marechal et al., 1997) . Mdm2 mRNA is almost undetectable at oocyte stage I/II. It increases slightly until oocyte stage V/VI when it reaches a maximum and then diminishes such that it is barely detectable after the blastula stage. These data suggest that Mdm2 protein may accumulate during oogenesis and may be required to modulate p53 activity during the ®rst mitosis. This also suggests that Mdm2 expression is not dependent on transcriptional activation by p53 during oogenesis, since p53 protein is stored as a large cytoplasmic pool until fertilization (Tchang et al., 1993) .
Is the essential role of Mdm2 as modulator of p53 limited to early embryonic development or does it last later in development or even in the dierentiation of adult tissues? A de®nitive answer to this question will await the development of inducible or tissue speci®c knockout of the Mdm2 gene. Preliminary information can be collected from expression studies or experiments with in vitro dierentiation models. A ubiquitous low level expression pattern was found throughout mouse embryonic development (Montes de Oca Luna et al., 1996) Restricted and reproducible expression patterns of Mdm2 were detected at particular stages of zebra®sh development (B Thisse, C Thisse and JP, unpublished results). These contrasting observations could possibly be reconciled by the recent proposal of an antiteratogenic function for p53 during development (Nicol et al., 1995; MacCallum et al., 1996; Hall and Lane, 1997) . A restricted activation of the p53 protein was noticed after gamma irradiation of mouse embryos: indeed, tissues showing important proliferative activities at the time of the teratogenic insult may display the strongest response, including activation of the Mdm2 gene (MacCallum et al., 1996; Gottlieb et al., 1997; Komarova et al., 1997 ). An additional role for Mdm2 in development of vertebrate embryos remains to be demonstrated.
Mdm2 and terminal dierentiation
Mdm2 mRNA was detected in various adult tissues with higher levels in brain, muscle or testis (Fakharzadeh et al., 1991; Shvarts et al., 1996) .
Evidence for a regulatory role for Mdm2 during muscle dierentiation was provided by Fiddler and colleagues (Fiddler et al., 1996) . In this study Mdm2 overexpression led to inhibition of MyoD-dependent transcription and dierentiation of C2C12 myoblasts. p53's transcriptional activity was recently shown to be required for the in vitro dierentiation of C2C12 myoblasts independently of the induction of cell cycle arrest: a direct role of the p53-Mdm2 loop in muscle dierentiaton is thus envisioned (Soddu et al., 1996) .
One of the most detailed studies of Mdm2 expression in an adult tissue was done on normal or reconstituted human skin (Dazard et al., 1997) . Surprisingly, high expression levels of p90 protein were found in the nuclei of cells in the most dierentiated layers of this tissue, although these cells are de®nitively withdrawn from the cell cycle. Thus, in contrast to what happens during muscle dierentiation, skin dierentiation could be accompanied by increased Mdm2 expression. Also, this expression was maintained in case of p53 inactivation by mutation or degradation by E6 protein, p53-independent expression of Mdm2 was also observed during dierentiation of F9 cells (Mayo and Berberich, 1996) . A careful analysis of other physiological situations could bring new examples which are in apparent contradiction with the p53-Mdm2 regulatory feedback loop model.
We discussed previously the structural and functional evidence for alternative functions of Mdm2. The absence of visible defects in p53-Mdm2 double knockout mice compared to p53 null mice should bring some doubt on the physiological relevance of these functions (Montes de Oca Luna et al., 1995; Jones et al., 1995) . Nevertheless, two important aspects were not taken into consideration in these studies, i.e. the in¯uence of the deletions on reproductive ®tness on one hand and the possible existence of compensatory pathways on the other. Perhaps relevant to the latter aspect is the recent discovery of Mdmx, an analog of Mdm2 (Shvarts et al., 1996; Shvarts et al., in press ). However, important dierences may exist between Mdm2 and Mdmx. Although the interaction between p53 and Mdmx is conserved, Mdmx transcription is not activated by p53. Also, Mdmx is clearly not able to compensate for the absence of Mdm2 with regard to the control of p53 activity in the Mdm2-null mice. The real functions of this new protein remain to be determined.
Concluding remarks
Mdm2 and p53 maintain an antagonistic relationship in which Mdm2 neutralizes its partner once p53 has accomplished its task in bene®t of the individual. Apparently, Mdm2 represents the bright side of the couple favoring proliferation and survival while p53 represents the dark side favoring growth arrest and death. However, too much Mdm2 increases the risk of cancer development. The recent characterization of the molecular interface between p53 and Mdm2 opens the way for a unique therapeutic approach of those tumors in which the p53 pathway is inactivated by Mdm2 overexpression. In this respect, experiments with synthetic peptides appear particularly promising for disrupting the interaction between the two proteins (BoÈ ttger et al., 1996) .
Mdm2 is only beginning to unravel its secrets. Keeping p53 activities under control is probably the major and surely the best understood of its functions. However, the exact role of the major part of the protein, notably the highly conserved C-terminal ring®nger, remains mysterious, as is the reason for the existence of a larger family of p53 binding proteins including Mdm2 and Mdmx. Particularly appealing is the perspective that these proteins will be at the crossroads of cellular proliferation, dierentiation and death. More surprises are likely to come.
